Skip to Content

'
Jatin J Shah, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Ohio State University College of Medicine, Columbus, OH, MD, Medicine
1997 Ohio State University, Columbus, OH, BS, Mechanical Engineering

Postgraduate Training

7/2004-6/2007 Clinical Fellowship, Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, James Foran
7/2002-6/2004 Clinical Residency, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, Craig Neilsen
7/2001-6/2002 Clinical Internship, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, Craig Neilsen

Board Certifications

11/2007 American Board of Internal Medicine, Hematology
11/2007 American Board of Internal Medicine, Oncology
8/2004 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Member, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2007-present

Institutional Committee Activities

Member, Multiple Myeloma Tissue Bank Steering Committee, Department of Lymphoma/Myeloma, Division of Cancer Medicine, 2007-present

Honors and Awards

2011 Who's Who in America
2007 Outstanding Research Fellow, University of Alabama at Birmingham
2006 Southern Society of Clinical Investigation Young Investigator Award
1993 Alpha Lambda Delta, Freshman Honor Society
1993 Phi eta Sigma, Freshman Honor Society
1992 Leadership Ohio State, Freshman Foundation Scholarship

Professional Memberships

American Association of Cancer Research
Member, 2006-present
American College of Physician- American Society of Internal Medicine
Member, 2001-present
American Medical Association
Member, 1997-present
American Society of Clinical Oncology
Member, 2004-present
American Society of Hematology
Member, 2004-present
American Society of Mechanical Engineers
Member, 1997-2002
National Associations of Inpatient Physicians
Member, 2001-2004
Ohio State Medical Association
Member, 1997-2001
SWOG
Member, 6/2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant, 2/2010.
2. Shah J., Wang W, Harrough VD, Saville W, Meredith R, Shen S, Mueh J, Lister S, Jasthy G, Maggass C, McKay R, Krumdieck M, Tharp C, Winter S, Gregory W, Buchholz S, Awasthi S, Jacobs H, Chung J, Egner AF, Lobuglio and Forero A. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 48(9):1736-44, 2007.
3. Forero A, Shah J, Carlisle R, Triozzi Pl, LoBuglio AF. Wang WQ, Fujimori M, and Conry RM. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 21(6):561-8, 2006.
4. Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle K, Conry R, LoBuglio AF, and Forero C. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm 21(6):553-60, 2006.
5. Shah JJ, Meredith R, Shen S, Nabors B, Lobuglio A, Yester M, Forero A. Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma 7(3):236-238, 2006.
6. Mace SE, Shah J. Observation medicine in emergency medicine residency programs. Acad Emerg Med 9(2):169-171, 2002.
7. Wen H, Shah J, and Balaban RS. Hall effect imaging. Biomed Eng 45(1):119-124, 1998.

Abstracts
1. Kay B Delasalle, Luhua Wang, Donna Weber, Sergio A. Giralt, Sheeba Thomas, Jatin Shah, Beverly Handy, Robert Z. Orlowski, and Raymond Alexanian. Curability of Multiple Myeloma. Blood 114:3864, 11/2009.
2. Nina Shah, Khawaja Fraz Ahmed, Sofia Qureshi, Jatin Shah, Robert Z Orlowski, Donna M Weber, Chitra Hosing, Uday Popat, Amin Alousi, Richard E Champlin, Sergio Giralt, Muzaffar Qazilbash. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood 114:1227, 11/2009.
3. Sofia Qureshi, Manish Sharma, Chitra Hosing, Floralyn L Mendoza, Jatin Shah, Amin Alousi, Paolo Anderlini, Partow Kebriaei, Issa F Khouri, Uday Popat, Marcos de Lima, Richard E Champlin, Sergio Giralt, Muzaffar H. Qazilbash. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood 114:4354, 11/2009.
4. Jatin J Shah, Andrzej J Jakubowiak, Owen A O’Connor, Robert Z Orlowski, Molly Patterson, Donald Harvey, Allison J Berger, Alice McDonald, George Mulligan, Lilli Petruzzelli, Michael D Pickard, Peter G Smith, Karthik Venkatakrishnan, Sagar Lonial. Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Blood 114:1854, 11/2009.
5. Sheeba K Thomas, Lei Feng, Kay B Delasalle, Michael Wang, Jatin J Shah, Robert Z Orlowski, Raymond Alexanian, and Donna M Weber. Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups. Blood 114:1668, 11/2009.
6. Nina Shah, Donna M Weber, Michael Wang, Sheeba Thomas, Jatin Shah, Sergio Giralt, Raymond Alexanian, Robert Z Orlowski, Muzaffar H. Qazilbash, Tiffany Avery. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood 114:1395, 11/2009.
7. J. J. Shah, A. Londhe, K. C. Lantz, C. Lowery, R. Z. Orlowski; University of Texas M. D. Anderson Cancer Center, Houston, TX; Centocor Ortho Biotech Services LLC, Horsham, PA. Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM). J Clin Oncol (ASCO Annual Meeting 2009) 27(15(s)):8591, 5/2009.
8. N. Shah, D. Weber, R. Orlowski, M. Wang, S. K. Thomas, T. Richards, S. Giralt, M. Qazilbash, R. Alexanian, J. J. Shah. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. J Clin Oncol (ASCO Annual Meeting 2009) 27(15s):8596, 5/2009.
9. Vince D. Cataldo, Michael A. Thompson, Bela B. Toth, Perpetua Sanjorjo, B. Nebiyou Bekele, Camilo Jimenez, William A. Murphy, Auris O. Huen, Rebecca B. Arbuckle, Michelle A. Fanale, Luis E. Fayad, Nathan Fowler, Larry W. Kwak, Peter W. McLaughlin, Sattva S. Neelapu, Barbara Pro, Alma Rodriguez, Jatin Shah, and Fredrick B. Hagemeister. Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid. Blood 112:5297, 11/2008.
10. Suzanne M. Cole, Rima Saliba, Matteo Pelosini, Floralyn L Mendoza, Donna Weber, Michael Wang, Sheeba Thomas, Robert Z. Orlowski, Jatin Shah, Amin Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Paolo Anderlini, Issa F. Khouri, Richard Champlin, Sergio Giralt, and Muzaffar H. Qazilbash. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood 112:3298, 11/2008.
11. Jorge Romaguera, Luis Fayad, Alma Rodriguez, Fb Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Jatin Shah, Pamela Weaver, Kim Hartig, Fernando Cabanillas, Larry Kwak, Hagop Kantarjian, and Michael Wang. Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). Blood 112:833, 11/2008.
12. Jatin Shah, Joan Blade, Jesus San Miguel, Pieter Sonneveld, Donghan Luo, Keith C Lantz, Colin Lowery, Jean-Luc Harousseau, and Robert Z. Orlowski. The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood 112:5192, 11/2008.
13. Jatin Shah, Joan Blade, Pieter Sonneveld, Jesus San Miguel, Donghan Luo, Keith C Lantz, Colin Lowery, Jean-Luc Harousseau, Robert Z. Orlowski. The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 112(5190) (#5190), 11/2008.
14. MN Saleh, I Percent, TE Wood, J Posey III, J Shah, R Carlisle, S Wojtowicz-Praga, A Forero-Torres. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. ASCO 2008 Annual Meeting (#3537), 2008.
15. J. Shah, S. Donegan, D. Wang, F. Robert. Incidence of Venous Thromboembolic Events and Effect on Survival in Patients with Lung Cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18s) (June 20 Supplement) (#18017), 2007.
16. J Shah, J Mueh, J Lister, et al. Safety and Efficacy of retreating follicular NHL with 90 Y Ibritumomab Tiuxetan (Zevalin). Journal of Investigative Medicine 55(1) (#330), 2007.
17. J. Shah, A. Forero, R. Carlisle, et al. Phase 1 Study of an Anti-GD3 Monoclonal Antibody, (KW-2871) in patients with Advanced Metastatic Melanoma. Journal of Investigative Medicine 54(1) (#189), 2006.
18. J. Shah, D. Harrough, W. Saville, et al. Safety and efficacy of retreating follicular non-Hodgkin's lymphoma (NHL) with 90Y ibritumomab tiuxetan. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24(18s) (June 20 Supplement) (#17528), 2006.
19. A. Forero-Torres, J. Shah et. al. A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL). Blood 106 (#4798), 2005.
20. J. Shah, A. Forero, R. Carlisle, P. Triozzi, A. Lobuglio, T. Kuwabara, A. Teitelbaum, M. Fujimori, M. Conry. Phase 1 Study of an Anti-GD3 Monoclonal Antibody, (KW-2871) in patients with Advanced Metastatic Melanoma. Journal of Clinical Oncology 23(16s) part I of II (June 1 Supplement) (#2556), 2005.
21. J. J. Shah, M. P.V. Gomes, S. R. Deitcher. Thromboelastographic (TEG) Characterization of Patients with Hematologic Malignancy and Chemotherapy Induced Thrombocytopenia (CIT). Blood 104 (#2729), 2004.
22. J. J. Shah, T. Mekhail, C. Comb, A. Leschinsky, C. Moon, P. Rayman, P. Elson, J. Finke, R. M. Bukowski. Renal cell cancer: Correlation of tumor characteristics with peripheral blood T cell NFκB activation and activation induced cell death (AICD). Proc Am Soc Clin Oncol 22:440 (#1766), 2003.

Manuals, Teaching Aids, Other Teaching Publications
1. Shah J, Richardson P, Mitsaides C. Multiple Myeloma Syllabus: Core Reading Collection for Hematology/Oncology Fellowship, 1/2006.

Grant & Contract Support

Title: Specialized Program of Research Excellence in Multiple Myeloma. Core D: Clinical Trials Core Facility
Funding Source: SPORE
Role: Co-Investigator
Duration: 2010 - 2015
 
Title: Targeting Met Tyrosine Kinase in Multiple Myeloma
Funding Source: Center for Targeted Therapy Disease-Specific Grant in Lymphoma/Myeloma
Role: Co-Principal Investigator
Principal Investigator: Varsha Gondhi, MD. PhD
Duration: 4/1/2008 - 4/1/2010

Last updated: 10/11/2010